Navigation Links
Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
Date:7/21/2008

ncluding, but not limited to the successful development of JUVISTA(R) (Human TGFb3) and veleglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire's filings with the Securities and Exchange Commission, including Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.

For further information please contact:

Investor Relations: Clea Rosenfeld (Rest of the World), +44-1256-894-160

Eric Rojas (North America), +1-484-595-8252

Media: Jessica Mann (Rest of the World), +44-1256-894-280

Matthew Cabrey (North America), +1-484-595-8248

Jessica Cotrone (North America), +1-617-613-4640


'/>"/>
SOURCE Shire Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
2. Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire
3. Application for Listing of Shire Limited Ordinary Shares
4. Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
5. Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
6. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
7. New Shire Holding Company Proposal
8. Shire to Introduce a New UK Listed Holding Company
9. Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
10. Shire plc: Long Term Incentive Plan
11. Shire plc: IFRS Results for the Year Ending December 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014   ISN ... & Safety Performance Indicators publication series. With ... of activity reported in 2013 within its online contractor ... and safety key performance indicator (KPI) statistics. ... Clients, U.S. publication is available in two ...
(Date:12/17/2014)... Based on the revenues gained from ... is dominated by four major players contributing to ... players include GE Healthcare (U.K.), Siemens AG (Germany), ... Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , ... attributed to its strong product portfolio, which includes ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2
... Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN)( ... Inc., its wholly owned subsidiary, announced today they have ... Army Medical Research and Materiel Command (USAMRMC) for consideration ... stem cells (ASCs) harvested from liposuction for treating Traumatic ...
... PARSIPPANY, N.J., May 4 Arno Therapeutics, Inc. (OTC ... oncology therapeutics, today announced that it has voluntarily filed ... ("SEC") in order to deregister its common stock under ... a result, effective immediately, Arno,s obligation to file periodic ...
... Develop Powerful Tools for Detecting Ovarian Cancer Earlier FRANKLIN ... (Becton, Dickinson and Company) (NYSE: BDX ) ... a worldwide development and supply agreement for oncology diagnostic ... develop diagnostic products that incorporate Fujirebio Diagnostics, cancer biomarkers ...
Cached Biology Technology:Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 3BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 2BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 3BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 4
(Date:11/21/2014)... Nov. 20, 2014 Strict laws against distracted ... piloting the North American and European automotive sector towards ... gesture recognition systems that are intuitive and able to ... the industry. New analysis from Frost ... Market in Europe and ...
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
(Date:11/12/2014)... 12, 2014 Crossmatch™, a leading provider of ... ® fingerprint readers have been deployed throughout Montparnasse ... Central Mexico . The bakery chain implemented the ... issues caused by employees clocking in for each other. ... readers, Montparnasse relied on paper timecards and a mechanical ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... infects more than 170 million people worldwide. Approximately 80 ... cirrhosis, cancer and also hepatic iron overload. A new ... School of Medicine reveals that HCV not only alters ... 1 (TfR1) but that TfR1 also mediates HCV entry. ...
... For more than a decade, scientists have suspected that hairpin-shaped ... scientists at NC State University have found the first example ... The research, published online in Proceedings of the ... describes how one strand of micro-RNA reduced by more than ...
... and the Woodrow Wilson International Center for Scholars are ... Foundation (NSF) to help realize potential benefits and to ... The grant is supported jointly by three units ... the Division of Environmental Biology, and the Engineering Directorate. ...
Cached Biology News:New Loyola study on hepatitis C virus entry factor 2
...
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml BL21 ... 0.2 ml BLT5615 glycerol stock , 1010 pfu ... Control Lysate , 50 l S-protein HRP Conjugate , ...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
... Kits are designed for ultra-sensitive detection ... or PVDF membranes. Since all necessary ... primary antibodies), the WesternBreeze Kits save ... protocol and getting your final results. ...
Biology Products: